Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06026709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effectiveness and Cost-effectiveness of Digital Psychological Intervention (EmoEase) in Chinese COPD Patients

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 13, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date: Sep 30, 2024 to Dec 30, 2025
    • Start date: Jun 1, 2024 to Oct 1, 2025
    • Study completion date: Jan 30, 2025 to Jan 30, 2026
    v3
  2. Notable Start date: Sep 15, 2023 to Jun 1, 2024v2 Show 5 more changesShow less
    • Primary completion date: Apr 15, 2024 to Sep 30, 2024
    • Study completion date: Jun 15, 2024 to Jan 30, 2025
    • Interventions: MindWellness (Behavioral) to EmoEase (Behavioral)
    • Study description expanded, about 228 words
    • Study title shortened, about 9 words
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
3,263 trials monitored
See 159 trials at risk
3,055 trials monitored
See 173 trials at risk
1,119 trials monitored
See 34 trials at risk
Background Mental health issues are common and often overlooked in COPD patients. Digital psychological interventions might help, but their effectiveness in Chinese COPD patients hasn't been studied. This study aims to develop and evaluate EmoEase, a digital psychological intervention, for its effectiveness and cost-effectiveness in improving mental wellbeing in Chinese COPD patients. Methods This multicenter, two-arm, randomized controlled trial (RCT) will enroll at least 420 COPD patients over 35 years old. Participants will receive either usual care (control group) or usual care plus EmoEase (intervention group). Assessments will occur at baseline (T0), 4 weeks (T1), 8 weeks (T2), and 16 weeks (T3). Participants will complete questionnaires and undergo physical measurements. The primary outcome will be mental wellbeing measured by the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS). Secondary outcomes will assess mental and physical health, COPD symptoms, health risk behaviors, socioeconomic factors, and healthcare use and costs. Analyses will use an intention-to-treat approach. Discussion This is the first RCT to evaluate EmoEase for COPD patients. If effective and cost-effective, EmoEase could be scaled up to provide mental health support to COPD patients in China.
Trial Details
NCT Number NCT06026709
Lead Sponsor Peking Union Medical College
Conditions
(from sponsor)
Chronic Obstructive Pulmonary Disease, Depression, Anxiety
Related terms Anxiety Disorders, Depression, Pulmonary Disease, Chronic Obstructive
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov